Beyond Time in Range: Hidden Statistical Challenges of Continuous Glucose Monitoring Data in Diabetes Drug Development

Abstract

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations guidance for industry, Investigators, and other stakeholders. 2023.

Zhan

Fisher

Zhang

XD.

Occurrence and impact of missing data on CGM metrics-analysis of data from type 1 Diabetes Exercise Initiative (T1DEXI). Diabetes. 2025; 74 (Suppl. 1):233-OR.

Braber

Braem

CIR

Vollenbroek -Hutten

MMR

, et al. Consequences of data loss on clinical decision-making in continuous glucose monitoring: Retrospective cohort study. Interact J Med Res. 2024;3:113.

Smith

Abraham

Bock

, et al. Impact of missing data on the accuracy of glucose metrics from continuous glucose monitoring assessed over a 2-week period. J Diabetes Sci Technol. 2023;25(5):356-362.

Kuang

Siddique

Scholtens

Imputation of missing continuous glucose monitor data. J Diabetes Sci Technol. 2025;31:193.

Wang

Kim

, et al. Statistical methods for handling missing data to align with treatment policy strategy. Pharm Stat. 2023;22(4):650-670.